Placeholder Banner

BIO Submits Comments on EPA’s Proposed Denial of Petitions for Rulemaking to Change the RFS Point of Obligation

February 22, 2017

The Biotechnology Innovation Organization (BIO) today submitted comments supportive of the Environmental Protection Agency’s Proposed Denial of Petitions for Rulemaking to Change the RFS Point of Obligation. In BIO’s view, granting the petitions to change the point of obligation would create unnecessary regulatory uncertainty and fail to further the statutory goals of the Renewable Fuel Standard (“RFS”) program.

Brent Erickson, executive vice president of BIO’s Industrial & Environmental Section, wrote in the comments:

“Because the oil industry is highly consolidated and vertically integrated, enforcing the RFS program at the right point in the supply chain is critical to ensure that key market players have the incentive to facilitate the goals of the program. Moving the point of obligation downstream would remove that imperative for refiners and inject uncertainty into the program, undermining the ability of market actors to plan for growth in renewable fuels use as mandated by Congress.

“Further, committing to one regulatory regime only to change the rules midstream hampers the RFS program’s goal of accelerating the commercialization of advanced and cellulosic biofuels. Changing the point of obligation would achieve just the opposite of that goal; it would increase program complexity, impose a set of new administrative and compliance costs and risks that would adversely affect a significant range of new entities, and undermine investor confidence in the broader renewable fuels industry just as cellulosic and other advanced biofuels are coming online.

“Also, as EPA rightly noted in its draft analysis of the Proposed Denial, market data does not justify changing the RFS point of obligation.”

BIO's comments are available at https://www.bio.org/letters-testimony-comments/bio-comment-epas-proposed-denial-petitions-rulemaking-change-rfs-point.

Discover More
Action plan outlines the policies needed to ensure that the biotechnology sector remains a driving force for America’s health, prosperity, national security, and geopolitical strengthWASHINGTON (November 10, 2026) - The Biotechnology Innovation…
Complaint argues HHS and CMS exceeded statutory authority; rule puts patient access, investment in future innovation, and America’s long-term biotechnology leadership at risk.WASHINGTON, DC & SAN DIEGO, CA & SAN FRANCISCO, CA - The…
WASHINGTON, DC (October 28, 2026) – Today, the Biotechnology Innovation Organization (BIO) and the Council of State Bioscience Associations (CSBA) released new national and state-level data on the U.S. bioscience industry’s economic impact…